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ORIGINAL ARTICLE
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ABSTRACT
Objective: This study aimed to compare the efficacy and safety of ossein-hydroxyapatite complex
(OHC) versus calcium carbonate (CC) for preventing bone loss during perimenopause in current clinical
practice.
Methods: The prospective, comparative, non-randomized, open-label study included 851 perimeno-
pausal women with basal bone mineral density (BMD) T-score 2 standard deviations (SDs).
Participants received either OHC (712mg calcium/day) or CC (1000mg calcium/day) over 3 years. BMD
was evaluated by dual-energy X-ray absorptiometry at the lumbar spine (L2–L4) at baseline and after
18 and 36months of follow-up. Adverse drug reactions (ADRs) were also recorded.
Results: In women receiving OHC, BMD at the L2–L4 site remained stable over the 3-year follow-up
period (mean [SD] change 0.00 [0.11] g/cm2). BMD in the CC arm decreased 3.1% (mean [SD] 0.03
[0.11] g/cm2). Between-group differences were statistically significant (p< 0.001) and favored OHC.
ADRs were more frequent in the CC group (7.7% vs. 2.7% in the OHC group; p¼ 0.001), affecting pri-
marily the gastrointestinal system.
Conclusion: OHC showed greater efficacy and tolerability than CC for bone loss prevention in peri-
menopausal women in real-world practice. As the daily dose of calcium was higher in the CC group,
the differences might be linked to the ossein compound in OHC.
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Introduction
The World Health Organization describes osteoporosis as a
‘progressive systemic skeletal disease characterized by low
bone mass and microarchitectural deterioration of bone tis-
sue, with a consequent increase in bone fragility and suscep-
tibility to fracture’1. The increased rate of fractures associated
with the disease is one of the most common causes of dis-
ability and a major contributor to medical care costs in many
regions of the world2. A recent systematic review showed
that insufficient calcium intake is a worldwide health prob-
lem with potentially serious consequences, particularly in
women and especially given the aging of the population3.
Research on osteoporosis in women has focused primarily
on the postmenopausal and elderly period. Nevertheless, an
accelerated rate of bone loss has also been reported during
the menopausal transition4,5, when estrogen secretion is
markedly reduced particularly in the year before the final
menstrual period and the first 2 years thereafter6.
Calcium, at a recommended daily intake of
700–1200mg7,8, is an important adjunctive therapy for the
treatment and prevention of osteoporosis when dietary
intake is insufficient7–9. Meta-analysis has shown it to be
more effective than placebo in reducing bone loss by the
second year of treatment10, and that it has a positive effect
on bone mineral density (BMD) and a tendency to reduce
fracture incidence.
Calcium carbonate (CC) is one widely used calcium sup-
plement when the recommended dietary calcium intake is
insufficient. Another supplement is ossein-hydroxyapatite
complex (OHC), which has also been shown to be effective
in maintaining BMD and to have a more intense osteogenic
effect than a calcium supplement alone after oral administra-
tion11–18. OHC consists of ossein, the protein that forms the
organic matrix of bone, and hydroxyapatite (Ca5[PO4]3OH),
the most relevant bone salt of vertebrate bone.
Little is known about the comparative effectiveness of cal-
cium supplements in the perimenopausal period. However,
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based on results from clinical trials14–18, our hypothesis was
that OHC might also be more effective than CC at preventing
bone loss in perimenopause. The aim of the present study
was therefore to compare the efficacy, safety, and tolerability
of OHC versus CC in preventing bone loss in perimenopausal
women over a 3-year treatment period in conditions of usual
clinical practice.
Methods
Study design and population
The PRevention of the Osteoporosis at the Perimenopausal
period (PROP) trial (ISRCTN83573042) was a Strengthening
The Reporting of OBservational Studies in Epidemiology
(STROBE)-compliant observational, prospective, multicenter,
open-label study performed between 2005 and 2014 in
accordance with the Declaration of Helsinki (2004) and local
legislation on data protection. Participants were followed for
up to 3 years and made a total of seven study visits (baseline
and 6, 12, 18, 24, 30, and 36months).
Participants were recruited consecutively in outpatient
gynecology clinics around Spain. As safety was one of the
main objectives of the study, and due to the relatively lim-
ited amount of tolerability data available for OHC, it was
planned to include participants at a ratio of 3:1 for OHC and
CC, respectively. Women were eligible to participate if they
met the following criteria: 40–50 years of age; perimeno-
pausal at study commencement; and lumbar or hip BMD
T-score 2 standard deviations (SDs) (normal BMD or mild
osteopenia) measured using dual-energy X-ray absorpti-
ometry (DXA) likely, in the opinion of the attending clinician,
to benefit from calcium supplementation. A participant was
considered perimenopausal if she reported menstrual irregu-
larity lasting less than 12 consecutive months not necessarily
associated with menopausal symptoms such as hot flushes,
vaginal dryness, or night sweats.
Patients were excluded if they had osteoporosis (BMD
T-score 2.5 SDs diagnosed using DXA) or severe osteope-
nia (BMD T-score <2 SDs), if they were being treated with
drugs with a known effect on bone metabolism (glucocorti-
coids, steroids, thyroid hormones, heparin [long-term treat-
ment], anticonvulsants, contraceptives, hormone replacement
therapy, lithium, cancer chemotherapy, selective estrogen
receptor modulators, calcium supplements, vitamin D,
immunosuppressive therapy, or bisphosphonates), or if they
had a diagnosis of hypercalcemia, hypercalciuria, or neoplasia
during the previous 5 years or osteomalacia, Paget bone dis-
ease, or diseases affecting bone metabolism. Pregnant
women, as well as those with reporting hypersensitivity to
any of the study drugs, or participants with gastrointestinal
disturbances that could interfere with drug absorption, were
also excluded.
Following a prescreening visit, all selected patients under-
went bone densitometry using DXA. Patients meeting the
selection criteria were included in the study after providing
informed consent.
Given that this was an observational study performed
under conditions of current clinical practice, no formal
sample size calculation was carried out. However, upon com-
pletion of the study, statistical power was calculated based
on the final number included and results from previous stud-
ies17, and was found to be sufficient to detect a difference
between the two treatment groups of at least 2% in lumbar
BMD after 3 years with a power of 85% and a significance
level of 5%, using the Student t-test for independent data.
Treatment
Based on the criteria of the participating clinicians, partici-
pants received either OHC at a dose of two 830-mg tablets
every 12 h (712mg of elemental calcium per day) or CC at
a dose of a single 1250-mg tablet every 12 h (equivalent to a
total daily dose of 1000mg of elemental calcium).
Of note, a single 830-mg OHC tablet (OsteoporVR /
OssopanVR /OsteogenonVR /Totalos PlusVR ; Pierre Fabre
Medicament, Castres, France) contains calcium (178mg),
phosphorus (82mg), and proteins associated with bone
metabolism (osteocalcin, 5.8 mg; type I collagen, 216mg; insu-
lin growth factor type I, 168 ng; insulin growth factor type II,
84 ng; transforming growth factor-b, 21 ng).
Assessments
Change in BMD was measured by DXA at the lumbar spine
(L2–L4) at baseline and after 18 and 36months of follow-up.
When possible, BMD assessments for the femoral neck, tro-
chanter, Ward’s triangle, and total hip were also sought.
All bone densitometries (baseline and follow-up) were per-
formed at the nearest reference center for each patient.
Adverse drug reactions (ADRs) associated with the treat-
ments were recorded, as well as the number of patients with
dose reduction due to toxicity and the number of patients
withdrawing due to treatment intolerance. Participating clini-
cians directly questioned patients on the presence of ADRs
and recorded their severity, duration, potential relation with
the study drug, action taken, and outcome.
The presence of fractures, the body mass index, and risk
factors for bone loss were recorded at the baseline visit.
Daily dietary calcium intake was estimated using a question-
naire to record weekly average consumption of the most fre-
quent food products.
At follow-up clinic visits, in addition to DXA assessments,
changes in concomitant medication, withdrawal from treat-
ment, and treatment compliance were recorded. Treatment
compliance was evaluated at each 6-month follow-up visit
by clinician interview. Patients were asked whether they took
the medication daily and whether they took the medication
at the prescribed dose. Possible responses for both questions
were: 1 ¼ ‘Never’, 2 ¼ ‘Almost never’, 3 ¼ ‘Almost always’,
and 4 ¼ ‘Always’. Patients were categorized as compliant
(>70% of doses taken) if they answered ‘Almost always’ or
‘Always’ to both questions.
Statistical analysis
Descriptive statistics used absolute values and proportions,
means, or medians as appropriate, together with measures
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of central tendency (SDs and interquartile ranges). Baseline
characteristics for the two treatment groups were compared
using Student’s t-test or the Mann–Whitney test and the chi-
square or Fisher’s exact test as appropriate.
The safety analysis was conducted on the safety popula-
tion, defined as all participants who took at least one dose
of the study medication. The cumulative incidence of each
type of ADR by cohort was estimated by dividing the num-
ber of patients with at least one recorded ADR by the total
number of exposed participants over the study. Cumulative
incidences were compared between groups using the chi-
square or Fisher’s exact test.
The initial efficacy analysis was performed in the full ana-
lysis set; that is, patients who fulfilled all selection criteria,
had taken the prescribed treatment with any degree of com-
pliance, and had at least one efficacy assessment. A second
efficacy analysis was performed using data from patients
with an average compliance of 70% or more. The analysis
was then repeated in both the overall and compliant-only
populations after excluding patients who began taking any
of the concomitant treatments described in the exclusion cri-
teria (e.g. hormone replacement therapy, contraceptives, or
isoflavones) while in the study. Treatment compliance was
also analyzed and compared across study arms.
Change in bone mass was assessed based on mean DXA
scores and expressed in grams per square centimeter and as
T-scores. Paired t-tests or Wilcoxon tests were used as appro-
priate to assess the statistical significance of any changes.
Analyses were performed using SAS v9.4 (SAS Institute
Inc, Cary, NC, USA), and all tests were two-sided with a sig-
nificance level of 0.05.
Results
A total of 1032 women were considered eligible for inclusion
in the study (Figure 1). Of these, 181 were excluded from
analysis because they failed to present at the first follow-up
visit (n¼ 127 [16.8%] in the OHC group and n¼ 54 [19.6%] in
the CC group). Data from 851 women were therefore avail-
able for the safety analysis (n¼ 629 in the OHC group and
n¼ 222 in the CC group). Of those who began the study,
722 (69.9%) patients completed 1 year of follow-up, 534
(51.7%) patients completed 2 years, and 437 (42.3%) patients
completed 3 years. Reported reasons for discontinuation in
the OHC and CC groups, respectively, were: loss to follow-up,
83% and 61%; concomitant disease, 10% and 6%; and
adverse effects, 7% and 33%.
For the efficacy analysis, 845 patients (99.3%) were
included in the full analysis set (624 in the OHC group and
221 in the CC group); 487 (57.6%) patients were eligible for
treatment-compliant analysis (n¼ 355 of the 624 patients
[56.9%] in the OHC group and 132 of the 221 patients
[59.7%] in the CC group). A total 57.6% (n¼ 487) of patients
reported a level of compliance, representing over 70% of
theoretical doses, with no statistically significant differences
between treatment groups.
There were no significant differences between the OHC
and CC groups for any of the baseline variables studied
(Table 1).
Change in bone mineral density
Table 2 presents the baseline BMD at the lumbar spine
(L2–L4) and the change after 36months of treatment in the
full analysis set population. The mean (SD) T-score in the
CC group decreased by 0.23 (0.76) over the study period,
compared to 0.01 (0.82) in the OHC group (difference in
change scores significant at p< 0.001). Over the same
period, bone density decreased by a mean (SD) of 0.03
(0.11) g/cm2 in the CC group but remained stable in the
OHC group (mean [SD] change 0.00 [0.11] g/cm2), with the
difference significant at p< 0.001 (Figure 2). After 3 years
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Figure 1. Study flow chart. CC, calcium carbonate; OHC, ossein-hydroxyapa-
tite complex.
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in Figure 3 (p< 0.001 for the difference between
study groups).
Changes in T-score and percentage changes at the lumbar
site are illustrated graphically for the two groups in Figures 2
and 3.
Calcium consumption
The mean (SD) daily calcium consumption for the full sample
was estimated at 993 (± 495) mg with no significant
Table 1. Baseline characteristics of the two study groups.
Variable OHC (n¼ 629) CC (n¼ 222) p-Value
Age (years), mean (SD) 47.3 (3.0) 47.1 (2.8) 0.485
Number of children (range 0–12), mean (SD) 1.9 (1.0) 1.9 (1.2) 0.627
Concomitant treatment (not calcium supplements), n (%) 131 (20.8) 41 (18.5) 0.452
Age at menarche (years), mean (SD) 12.2 (1.4) 12.3 (1.4) 0.268
Past contraceptive treatment, n (%) 213 (42.6) 86 (45.7) 0.458
Duration (years), mean (SD) 7.0 (4.4) 6.6 (4.5) 0.572
Menstrual cycle
Regular (last 12 months), n (%) 191 (30.9) 70 (32.3) 0.531
Periodicity changes (last 3 months), n (%) 228 (36.9) 71 (32.7) 0.452
Amenorrhea (last 3–11 months), n (%) 199 (32.2) 76 (35) 0.458
Risk factors (habits)
Smoking status
Current smoking, n (%) 172 (27.9) 73 (33.2) 0.137
Cigarettes per day, mean (SD) 13.5 (8.4) 14.1 (7.5) 0.583
Smoking habit (years), mean (SD) 19.8 (7.9) 18.1 (8.7) 0.157
Former smoker, n (%) 60 (23.4) 16 (19.3) 0.429
Years after smoking cessation, mean (SD) 8.6 (6.5) 11.6 (6.4) 0.108
Frequent alcohol use 47 (7.9) 19 (8.6) 0.732
Drinks a day (units), mean (SD) 1.50 (0.76) 1.42 (0.51) 0.681
Caffeine use, n (%) 249 (44.6) 100 (50.3) 0.171
Reported calcium intake (mg/day), mean (SD) 992 (503) 996 (475) 0.973
Regular exercise, n (%) 226 (44.1) 92 (47.9) 0.358
CC, calcium carbonate; OHC, ossein-hydroxyapatite complex; SD, standard deviation.
Table 2. Evolution of bone mineral density (T-scores and grams per square centimeter) at the lumbar spine (n¼ 807).
Ossein-hydroxyapatite complex Calcium carbonate




Baseline 601 0.61 (1.11) – 206 0.75 (0.98) – 0.250
V7 – baseline 299 0.01 (0.82) 0.19 107 0.23 (0.76) 0.001 <0.001
BMD (g/cm2)
Baseline 578 1.03 (0.15) – 204 1.01 (0.13) – 0.057
V7 – baseline 280 0.00 (0.11) 0.34 102 0.03 (0.11) <0.001 <0.001
BMD, bone mineral density; SD, standard deviation; V7, visit at 36months of follow-up.
aWilcoxon test for change from baseline within groups.
bMann–Whitney U-test for difference between treatment groups.
Figure 2. Lumbar T-score change (mean) from baseline in the study arms
(L2–L4). CC, calcium carbonate; OHC, ossein-hydroxyapatite complex.
Figure 3. Mean percentage change from baseline in the study arms (L2–L4).
CC, calcium carbonate; OHC, ossein-hydroxyapatite complex.
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differences between the arms (Table 1). There was consider-
able variability in intake among participants, with 12.2% of
the patients having a daily intake 500mg, 22.4% between
501 and 800mg, 18.9% between 801 and 1000mg, 33.6%
between 1001 and 1500mg, and 12.8% of the patients with
intake >1500mg.
Subgroup analysis
After excluding patients who began taking any treatment
described in the exclusion criteria section after study initi-
ation, lumbar BMD results in the remaining population
(n¼ 672) showed a mean (SD) T-score increase of 0.09 (0.79)
in the OHC arm (n¼ 224) and a decrease of 0.23 (0.70) in
the CC group (n¼ 76) by study end (p< 0.001 for between
groups differences). The mean (SD) change for this subgroup
was 0.01 (0.11) g/cm2 in the OHC arm, which represented an
increase of 0.96%, compared to a mean change of 0.03
(0.10) g/cm2, or a decrease of 3.1%, in the CC group
(p< 0.001 for difference between arms).
BMD results were similar when the analyses were re-run
in compliant patients (n¼ 487), with OHC patients (n¼ 281)
showing a mean (SD) increase in lumbar T-score of 0.03
(0.80) and CC patients (n¼ 101) showing a mean decrease of
0.27 (0.72) (p< 0.0001 between groups). The mean (SD)
change in compliant patients was 0.00 (0.11) g/cm2, or no
change, in the OHC arm and a decrease of 0.03 (0.10) g/
cm2 in the CC group, representing a change of 3.1%
(p< 0.001 for the between-group difference).
Finally, in compliant patients who took no drugs which
could potentially affect BMD other than the study drugs
(n¼ 361), by study end there was a mean (SD) change in
lumbar T-score of 0.10 (0.79) in the OHC arm (n¼ 214) and a
change of 0.27 (0.69) in the CC arm (n¼ 71). The difference
in the size of the change between groups was statistically
significant at p< 0.0001. In the same population, the mean
(SD) change was 0.01 (0.11) g/cm2 in the OHC arm, which
represented an increase of 0.96%, compared to 0.03 (0.10)
g/cm2 in the CC group, which represented a change of
3.1% (p< 0.001 for the difference between groups).
Patients with osteoporosis at study end
In patients who took no drugs which could potentially affect
BMD except for the study drugs (n¼ 672), the BMD test
results indicated the presence of osteoporosis in 0.8% (n¼ 4)
of the OHC group and in 3.0% (n¼ 5) of the CC arm
(p< 0.05 for the between-group difference).
Similar results were observed in the same group when
only compliant patients were evaluated (n¼ 361), with 1.5%
(n¼ 4) in the OHC arm and 5.6% (n¼ 5) in the CC group
showing osteoporosis (p< 0.05 for the difference
between groups).
Reported fractures by treatment group
No clinical vertebral fractures were reported during follow-
up. However, 19 patients (2.3%) suffered a bone fracture
which, in most cases, was assumed to be caused by high-
impact trauma. The rate was higher in the CC group at 3.7%
(n¼ 8), compared to 1.8% (n¼ 11) in the OHC group,
although the difference was not statistically significant.
Tolerability
A total of 34 patients reported at least one ADR (see Table
3) (n¼ 17 in each group, or 2.7% and 7.7% for the OHC and
CC group, respectively; p¼ 0.001). ADRs were considered
mild. A total of 10 patients withdrew from the study because
of ADRs; two (0.3%) in the OHC group and eight (3.6%) in
the CC group (p< 0.001).
The majority of ADRs were gastrointestinal: 13 patients
(2.1%) in the OHC group and 13 (5.9%) in the CC group
reported gastrointestinal ADRs at some point in the study
(p< 0.005). No cardiovascular events were reported.
Discussion
To our knowledge, this is the first study to comparatively
evaluate the long-term efficacy, safety, and tolerability of
OHC versus CC for bone loss prevention during
perimenopause.
Lumbar BMD was maintained in patients treated with
OHC but decreased significantly (3.1%) over the 3-year fol-
low-up period in patients treated with CC.
The results observed here are similar to those reported in
previous studies comparing OHC and CC. In a randomized,
open-label, 2-year follow-up study carried out in non-
osteoporotic postmenopausal women17, patients treated
with OHC maintained their BMD while patients treated with
CC had a 3.7% BMD loss by the study end. Similar trends
were observed in trials comparing the two drugs in postme-
nopausal women with18 or without15 bone fractures and in
elderly patients with osteoporosis14,19. In a meta-analysis of
randomized controlled trials which compared OHC and CC,
OHC proved to be substantially more effective in preventing
bone loss than CC13.
The difference in efficacy between the two calcium sup-
plements does not seem to be related exclusively to the
dose of calcium supplementation, as the amount of calcium
provided by CC was 40.4% higher that provided by OHC.
Table 3. Reported adverse drug reactions.
Adverse drug reaction (ADR) OHC (n¼ 629) CC (n¼ 222) p-Value
Total affected patients 17 (2.7) 17 (7.7) 0.001
Patients with gastrointestinal complaintsa 13 (2.1) 13 (5.9) 0.005
Headache 3 (0.5) 1 (0.5) 1.000b
Dizziness 0 1 (0.5) 0.261b
Dysgeusia 0 1 (0.5) 0.261b
Back pain 0 1 (0.5) 0.261b
Eczema 1 (0.2) 0 1.000b
Weight gain 1 (0.2) 0 1.000b
Dry mouth 1 (0.2) 1 (0.5) 0.454b
Data presented as n (%).
CC, calcium carbonate; OHC, ossein-hydroxyapatite complex.
aIncluding dyspepsia, abdominal pain, flatulence, vomiting, and esophagitis.
bNot statistically significant.A patient could report more than one ADR.
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The difference in efficacy might be explained by the osteo-
genic effects associated with OHC’s organic component,
ossein, as suggested by several authors11,12,15,20.
Proteins present in OHC (osteocalcin, insulin growth factor
type I, insulin growth factor type II, transforming growth fac-
tor-b) are considered mitogenic for bone cells in vitro21–23
and could improve bone formation in vivo as observed in dif-
ferent studies11,12,14,15, although the process is not com-
pletely understood.
The osteogenic hypothesis seems to be confirmed by the
results of a randomized controlled trial which compared the
effects of OHC and CC on bone metabolism in women with
osteoporosis aged >65 years without prevalent fractures14.
After 3 years of treatment, it was observed that mean levels
of serum osteocalcin significantly increased in patients
treated with OHC in comparison with those receiving CC,
indicating a greater anabolic effect of OHC on bone.
Both treatments were well tolerated, although OHC
appeared to be better tolerated than CC and there was a
lower rate of withdrawals due to ADRs in OHC patients. The
rates of ADRs observed are similar to those reported in a
4-year follow-up study which evaluated the role of OHC in
the prevention of bone loss24. The presence of ADRs is
important as this can affect treatment adherence, as reported
in a study which showed a statistically significant association
between the incidence of adverse effects and reduced adher-
ence to calcium and vitamin D supplementation in patients
attending centers specializing in osteoporosis25.
Limitations and strengths
Limitations of this study include the fact that treatments
were non-randomized. Although randomized controlled trials
are considered the gold standard for evaluating the effective-
ness of medical interventions, observational studies have
strengths as well, particularly when the aim is to investigate
efficacy and safety in conditions of real-world practice. The
risk of bias in the study was reduced by the fact that there
were no significant differences between the two study
groups at baseline and treatment compliance between both
groups was similar, ensuring comparability. Further strengths
of the study included the long-term follow-up and the fact
that this is the largest sample to date in which the long-term
safety and efficacy of OHC and CC have been compared in a
population of perimenopausal women.
A dropout rate of 57.7% could also be considered a limi-
tation of the study, although those levels of dropout are fre-
quently observed in clinical practice26–28. The majority of the
dropouts were due to loss to follow-up, although adverse
effects and concomitant diseases were also reported.
Nevertheless, the final sample was sufficiently large to detect
statistically significant differences between study groups on
the outcomes of interest.
Finally, as the study was intended to assess efficacy and
tolerability in real-world clinical practice, the DXA tests were
carried out in health centers located in the cities where the
patients lived rather than in a sole location. This could have
led to slight differences in the coefficient of variation
between centers due to the use of different bone densitome-
ters. Nevertheless, this is likely to have had only a limited
influence on the results and any potential bias due to the
use of different densitometers across centers can also be
assumed to affect both groups equally. It is also relevant to
note that the 3.1% reduction in lumbar BMD in the CC group
in comparison with the OHC group is likely to be clinically
relevant, as it is greater than the 2.6% difference observed in
the MORE study between raloxifene and placebo, which was
shown to be associated with increased risk of vertebral frac-
ture in the placebo group29.
Conclusions
This study has shown that OHC appears to be significantly
more effective than CC at preventing bone loss in the peri-
menopausal period. Both drugs had a good long-term safety
profile although OHC appeared to be better tolerated than
CC, especially as regards gastrointestinal events. Given that
the calcium dose was approximately 40% higher in the CC
group, the superior efficacy of OHC appears to be connected
with its ossein constituent. Further research is warranted to
confirm the results observed in this study.
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Barcelona: Albert Casali, C.; Bernard Julian, A.; Beroiz Fernandez, P.;
Feriche Adell, M.; Garrido Salda~na, A.; Saceda Lopez, M.R.; Bilbao:
Apodaca Santiesteban, L.A.; Cantabria: Ceballos Rodrıguez, M.C.;
Castellon: Goberna Burguera, J.; Vilar Igual, M.; Guadalajara: Abollado
Fernandez, J.L.; Las Palmas: Latorre Alcazo, M.C.; Sosa Marrero, M.; Leon:
Carriles Sastre, R.; Lugo: Fandi~no Garcıa, M.D.; Madrid: De Castro
Martınez, P.; De la Calle Fernandez-Miranda, M.; Martın Dıaz, V.; Martın
Escanciano, F.J.; Mu~noz Fernandez, M.T.; Pelayo Delgado, I.; Perez
Maceda, J.M.; Piernas Morales, C.; Pino Villalba, M.P.; Prieto Amorın, A.I.;
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Casasus, M.J.; Cervera Sanchez, J.; De Gonzalo Santos, A.; Flor Civera,
M.F.; Garcıa Loscos, J.M.; Marı Sanchez, M.F.; Negueroles Albuixech, R.;
Perez Garcilaso, J.; Rodenas Palazon, J.J.; Zamora: Garcıa Gonzalez, C.E.;
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